Finally, we confirmed that BLNK and CD210 expressions were significantly lower in our newly identified subsets of interest: IgA+CD20+ (Figure 5a–c), IgG1+ (Figure 5d, e) and IgG2+ (Figure 5f, g) B cells in people with MS. The gene discussed is CD79A; the disease is myeloid sarcoma.